This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Schrier, R. W. Search for Related Content PubMed PubMed Citation Articles by Schrier, R. W. Pubmed/NCBI databases Medline Plus Health Information High Blood Pressure

(Hypertension. 2000;35:1031.)
© 2000 American Heart Association, Inc.

Scientific Contributions

Diuretic Treatment of Systolic Hypertension in the Elderly

Robert W. Schrier

From the Department of Medicine, University of Colorado Health Sciences Center, Denver, Colo.

Correspondence to Robert W. Schrier, MD, Department of Medicine, University of Colorado Health Sciences Center, Box B-178, 4200 E Ninth Ave, Denver, CO 80262.

Key Words: diuretics • hypokalemia • elderly

	Introduction

 
The publication, in 1991, of the results of the Systolic Hypertension in the Elderly Program (SHEP) constituted a major therapeutic advance for treating isolated systolic hypertension–systolic blood pressure 160 to 219 mm Hg and diastolic blood pressure <90 mm Hg in patients >60 years of age.¹ The results demonstrated not only a decrease in strokes but also coronary heart disease. In earlier studies, the ability to demonstrate a beneficial effect of treating combined systolic diastolic hypertension on the incidence of coronary heart disease was difficult to demonstrate: one possibility that was entertained to explain the difficulty was related to the dose of diuretic used. The relatively high doses of thiazide diuretics (50 to 100 mg/d) used in previous hypertension studies may have increased ventricular arrhythmias and sudden deaths and worsened glucose and lipid profiles, secondary to the occurrence of hypokalemia. These effects could have obscured any beneficial effects that lowering blood pressure has on the occurrence of coronary heart disease. In the SHEP study, a lower dose of chlorthalidone was used, generally starting with 12.5 mg/d and only increasing to a maximum of 25 mg/d. If the goal of lowering systolic blood pressure to <160 mm Hg or by 20 mm Hg was not achieved, the ß-blocker atenolol or reserpine was added.

As noted in this issue of Hypertension, in spite of the lower doses of chlorthalidone, a thiazide diuretic, 7% of the active treatment group versus 1% of the placebo group had a serum potassium concentration <3.5 mEq/L . . . [Full Text of this Article]